| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PHACS |
| Uniprot No | Q96QU6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-501 aa |
| 活性数据 | MFTLPQKDFR APTTCLGPTC MQDLGSSHGE DLEGECSRKL DQKLPELRGV GDPAMISSDT SYLSSRGRMI KWFWDSAEEG YRTYHMDEYD EDKNPSGIIN LGTSENKLCF DLLSWRLSQR DMQRVEPSLL QYADWRGHLF LREEVAKFLS FYCKSPVPLR PENVVVLNGG ASLFSALATV LCEAGEAFLI PTPYYGAITQ HVCLYGNIRL AYVYLDSEVT GLDTRPFQLT VEKLEMALRE AHSEGVKVKG LILISPQNPL GDVYSPEELQ EYLVFAKRHR LHVIVDEVYM LSVFEKSVGY RSVLSLERLP DPQRTHVMWA TSKDFGMSGL RFGTLYTENQ DVATAVASLC RYHGLSGLVQ YQMAQLLRDR DWINQVYLPE NHARLKAAHT YVSEELRALG IPFLSRGAGF FIWVDLRKYL PKGTFEEEML LWRRFLDNKV LLSFGKAFEC KEPGWFRFVF SDQVHRLCLG MQRVQQVLAG KSQVAEDPRP SQSQEPSDQR R |
| 分子量 | 57.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
由于“PHACS”蛋白在主流科学文献中并无明确记载，可能存在拼写错误或非标准缩写。以下提供几篇与重组人蛋白相关的研究范例，供参考：
---
1. **文献名称**：*Expression of Recombinant Human Albumin in Pichia pastoris*
**作者**：Sleep, D. et al.
**摘要**：该研究在毕赤酵母中高效表达重组人血清白蛋白(HSA)，优化了发酵工艺，获得高产量、高纯度的蛋白，为生物制药提供了经济方案。
2. **文献名称**：*Production of Recombinant Human Insulin in Escherichia coli*
**作者**：Goeddel, D.V. et al.
**摘要**：开创性地利用大肠杆菌表达重组人胰岛素，通过基因工程手段合成人胰岛素前体，并验证其生物活性，奠定了胰岛素工业化生产的基础。
3. **文献名称**：*Recombinant Human Growth Hormone: Structure and Therapeutic Applications*
**作者**：Lewis, U.J. et al.
**摘要**：系统阐述了重组人生长激素(rhGH)的结构特征，并评估其在生长激素缺乏症治疗中的临床效果，强调了其安全性与有效性。
4. **文献名称**：*Engineering and Characterization of a Stabilized VEGF-B Fusion Protein*
**作者**：Olofsson, B. et al.
**摘要**：设计了一种重组VEGF-B融合蛋白，通过点突变增强其稳定性，证实其在促进血管生成中的功能，为心血管疾病治疗提供新策略。
---
**建议**：若PHACS为特定研究中的非标准命名，请核实其全称(如是否涉及磷酸酶、乙酰化酶或支架蛋白)，或查阅课题相关文献。亦可通过基因数据库(如UniProt、NCBI Gene)确认基因符号，以便精准检索。
Recombinant human PHACS (Proline-Hydroxylase-Associated Coiled-Coil Protein) is a synthetic protein engineered to study and harness the biological functions of its naturally occurring counterpart. PHACS is a cytoplasmic protein characterized by its coiled-coil domains, which facilitate protein-protein interactions. It binds to prolyl hydroxylases (PHDs), enzymes critical for oxygen-dependent regulation of hypoxia-inducible factors (HIFs) and collagen biosynthesis. By modulating PHD activity, PHACS influences cellular responses to hypoxia and extracellular matrix remodeling.
Recombinant PHACS is typically produced using expression systems like *E. coli* or mammalian cell cultures, enabling scalable purification for research applications. It serves as a tool to investigate molecular mechanisms underlying diseases linked to HIF dysregulation, such as cancer, ischemic disorders, and fibrosis. Additionally, its role in collagen post-translational modification highlights relevance in connective tissue disorders. Pharmaceutical studies leverage recombinant PHACS to screen potential therapeutics targeting HIF pathways or collagen-related pathologies. Recent advances also explore its utility in bioengineering scaffolds for tissue repair.
Despite progress, challenges persist in understanding PHACS’s full interactome and tissue-specific functions. Ongoing research aims to clarify its regulatory roles in metabolic and hypoxic signaling, offering potential insights for precision medicine and regenerative therapies.
×
